

A pro-convulsive carbamazepine metabolite: Quinolinic acid in drug resistant epileptic human brain

Chaitali Ghosh ^{a,c,d}, Nicola Marchi ^{a,c,d,*}, Mohammed Hossain ^{a,c,d}, Peter Rasmussen ^c,
Andreas V. Alexopoulos ^e, Jorge Gonzalez-Martinez ^{c,e}, Hu Yang ^{f,g}, Damir Janigro ^{a,b,c,d,*}

^a Cerebrovascular Research, Cleveland Clinic Foundation, Cleveland, OH, USA

^b Department of Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA

^c Department of Neurological Surgery, Cleveland Clinic Foundation, Cleveland, OH, USA

^d Department of Cell Biology, Cleveland Clinic Foundation, Cleveland, OH, USA

^e Epilepsy Center, Cleveland Clinic Foundation, Cleveland, OH, USA

^f Department of Biomedical Engineering, School of Engineering, Virginia Commonwealth University, Richmond, VA, USA

^g Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA

ARTICLE INFO

Article history:

Received 18 October 2011

Revised 21 February 2012

Accepted 1 March 2012

Available online 9 March 2012

Keywords:

Blood–brain barrier

Drug resistance

Drug metabolism

Drug delivery

Carbamazepine

Pharmacokinetics

In vitro models

Tissue engineering

Neurotoxicity

Pharmacogenomics

ABSTRACT

Drugs and their metabolites often produce undesirable effects. These may be due to a number of mechanisms, including biotransformation by P450 enzymes which are not exclusively expressed by hepatocytes but also by endothelial cells in brain from epileptics. The possibility thus exists that the potency of systemically administered central nervous system therapeutics can be modulated by a metabolic blood–brain barrier (BBB). Surgical brain specimens and blood samples (*ex vivo*) were obtained from drug-resistant epileptic subjects receiving the antiepileptic drug carbamazepine prior to temporal lobectomies. An *in vitro* blood–brain barrier model was then established using primary cell culture derived from the same brain specimens. The pattern of carbamazepine (CBZ) metabolism was evaluated *in vitro* and *ex vivo* using high performance liquid chromatography–mass spectroscopy. Accelerated mass spectroscopy was used to identify ¹⁴C metabolites deriving from the parent ¹⁴C-carbamazepine.

Under our experimental conditions carbamazepine levels could not be detected in drug resistant epileptic brain *ex situ*; low levels of carbamazepine were detected in the brain side of the *in vitro* BBB established with endothelial cells derived from the same patients. Four carbamazepine-derived fractions were detected in brain samples *in vitro* and *ex vivo*. HPLC-accelerated mass spectroscopy confirmed that these signals derived from ¹⁴C-carbamazepine administered as parental drug. Carbamazepine 10, 11 epoxide (CBZ-EPO) and 10, 11-dihydro-10, 11-dihydroxy-carbamazepine (DiOH-CBZ) were also detected in the fractions analyzed. ¹⁴C-enriched fractions were subsequently analyzed by mass spectrometry to reveal micromolar concentrations of quinolinic acid (QA). Remarkably, the disappearance of carbamazepine-epoxide (at a rate of 5% per hour) was comparable to the rate of quinolinic acid production (3% per hour). This suggested that quinolinic acid may be a result of carbamazepine metabolism. Quinolinic acid was not detected in the brain of patients who received antiepileptic drugs other than carbamazepine prior to surgery or in brain endothelial cultures obtained from a control patient.

Our data suggest that a drug resistant BBB not only impedes drug access to the brain but may also allow the formation of neurotoxic metabolites.

© 2012 Elsevier Inc. All rights reserved.

Introduction

Drug resistance in epilepsy represents an unsolved clinical problem. While a number of new anti-epileptic drugs (AED) have become available in the past years, seizures continue to be poorly controlled by

these AEDs in approximately 25–30% of patients (Kwan et al., 2011). It is not clear whether AEDs fail to exert their effect due to pharmacokinetic or pharmacodynamic mechanisms, or a combination of the two. It has been suggested that multiple drug resistance may be a pathology distinct from epilepsy, one that requires a specific treatment (Granata et al., 2009). Recent evidence suggested the presence of P450 enzymes in the drug resistant epileptic (DRE) human brain (Ghosh et al., 2010, 2011a, 2011b). Specifically, enzymes responsible for the metabolism of AEDs (e.g., CYP3A4 metabolizing carbamazepine, CBZ) are over-expressed by drug resistant blood–brain barrier endothelial cells

* Corresponding author at: Cleveland Clinic Foundation, NB-20 LRI 9500, Euclid Avenue, Cleveland, OH 44195, USA. Fax: +1 216 445 1466.

E-mail addresses: marchin@ccf.org (N. Marchi), janigrd@ccf.org (D. Janigro).

Available online on ScienceDirect (www.sciencedirect.com).

(DRE BBB) and by neurons. Interestingly, while other drug resistant molecules such as MDR1 are almost ubiquitously expressed in central nervous system (CNS) cells from epileptic resections, we failed to observe any glial expression of CYP3A4 (Ghosh et al., 2011a).

It still remains unclear whether brain-specific enzymatic machinery is responsible for the metabolism of AEDs and insufficient drug levels in the resistant brain. However, it is often assumed that most of the metabolic burden of drug metabolism is hepatic but increasing evidence points to the CNS as a drug metabolizing organ (Ghosh et al., 2010, 2011a, 2011b). The concomitant CNS expression of MDR1 and P450 enzymes in the drug resistant epileptic brain suggests that the bioavailability of AEDs is dictated by mechanisms similar to those used by the liver as the principal drug-metabolizing organ (Ghosh et al., 2010). The presence of a BBB machinery to manage drug fate is an important finding, since a local metabolic process may allow the formation and uncontrolled accumulation in the brain of molecules with unexpected functions or even toxicity. These may further confound brain pharmacology under pathological conditions associated with multiple drug resistance (Dombrowski et al., 2001; Loscher and Potschka, 2005; Marchi et al., 2010a).

While P450 enzymes are involved in virtually all CNS drug metabolisms, for this study we focused on the pattern of CBZ biotransformation. Similarly, while multiple drug resistance is a common clinical challenge (Granata et al., 2009; Loscher and Potschka, 2005), we focused on epilepsy due in part to the availability of tissue samples and detailed understanding of the molecular players involved. While details on intermediate metabolites of CBZ at the BBB are scant, hepatic CBZ metabolism has been extensively studied (Breton et al., 2005; Ju and Uetrecht, 1999). CBZ transformation by hepatocytes consists of an oxidation step by CYP3A4 and formation of carbamazepine-10,11-epoxide (CBZ-EPO). Excretion occurs after hydroxylation to CBZ-10,11-trans-dihydrodiol and Phase II conjugation. Since CYP3A4 is prominently expressed at the DRE BBB (Ghosh et al., 2010), we wished to test the hypothesis that a local CNS metabolism of CBZ occurs differently in drug resistant epileptic brain. This was achieved by use of a combined *ex vivo* (brain and blood samples)/*in vitro* (a model of the DRE BBB) experimental approach previously validated in a comparable experimental setting (Cucullo et al., 2007; Cucullo et al., 2008; Desai et al., 2002; Ghosh et al., 2010, 2011a; Grant et al., 1998). To detect and trace CBZ, we took advantage of a combination of analytical techniques; including high performance liquid chromatography (HPLC), mass spectrometry (MS) and

accelerated mass spectrometry (AMS) (Tompkins et al., 2006) to profile the CBZ biotransformation by the BBB and in a drug resistant brain.

Materials and methods

Recruitment of subjects

The investigation conforms to the principles outlined in the Declaration of Helsinki. Patient consent was obtained as per the Institutional Review Board instructions. Epileptic patients were selected according to the antiepileptic drug administered before resection. Patients received carbamazepine or other AEDs (n=9) prior to surgery as part of their anti-epileptic drug schedule (Table 1). As a control we used a patient that was surgically operated due to cerebral aneurysm and administered AED prior to surgery. Brain and blood samples were collected as described in Fig. 1 and as reported in our previous studies (Ghosh et al., 2010, 2011a). Brain and blood samples were used for determination of CBZ metabolites using HPLC paired to accelerator mass spectroscopy (AMS) or conventional mass spectroscopy (MS). Primary brain endothelial cells were established from brain specimens and used for *in vitro* studies (Cucullo et al., 2008; Ghosh et al., 2010; Santaguida et al., 2006).

Endothelial cells

Primary endothelial cells were isolated from secondary branches of middle cerebral arteries of brain specimens from patients undergoing temporal lobectomies to relieve medically intractable seizures or removed from aneurysm domes. Cell culture methods are as described in details elsewhere (Desai et al., 2002; Dombrowski et al., 2001; Ghosh et al., 2010).

Dynamic *in vitro* model (DIV)

DIV modules were purchased from Spectrum (catalog. no. 400–025, Spectrum Lab, CA, USA) or Flocel Inc. (Cleveland, OH). Each module consists of hollow polypropylene capillaries embedded in a clear plastic chamber. The capillaries are connected with a reservoir for media and a pulsatile pump apparatus. We used a flow rate of 4–5 ml/min corresponding to a shear stress of 3–10 dyn/cm².

Table 1
Demographic characteristics of the patients in this study.

Patient id	Pathology	Age (yrs.)	Gender	Classification	Age of seizure onset	Seizure frequency	AED taken before surgery
Patient 1	Drug resistant temporal lobe epilepsy (DRE-1)	41	F	Temporal lobe epilepsy	18 months	Initially 4–8/month; with LEV 4/month	CBZ 12 h before surgery Other AEDs: LEV
Patient 2	Drug resistant temporal lobe epilepsy (DRE-2)	28	F	Temporal lobe epilepsy	14 yrs. old	90/month	CBZ 2 h before surgery Other AEDs: LEV
Patient 3	Drug resistant temporal lobe epilepsy (DRE-3)	27	M	Temporal lobe epilepsy	20 yrs. old	0.2/month	CBZ 14 h before surgery Other AEDs: LEV
Patient 4	Drug resistant temporal lobe epilepsy (DRE-4)	11	M	Temporal lobe epilepsy	4 yrs. old	90/month	CBZ 17 h before surgery Other AEDs: LEV
Patient 5	Drug resistant temporal lobe epilepsy (DRE-5)	56	F	Temporal lobe epilepsy	46 yrs. old	0.16 clusters/month	CBZ 18 h before surgery Other AEDs: LMT
Patient 6	Drug resistant temporal lobe epilepsy (DRE-6)	35	F	Temporal lobe epilepsy	NA	NA	CBZ 8 h before surgery Other AEDs: TPM
Patient 7	Cerebral aneurysm	46	F	Non-ruptured cerebral aneurysm	NA	NA	TPM before surgery
Patient 8	Drug resistant temporal lobe epilepsy (DRE-7)	28	F	Temporal lobe epilepsy	16 yrs. old	6/month	LMT, GBP, PGB 2 h before surgery
Patient 9	Drug resistant temporal lobe epilepsy (DRE-8)	45	F	Temporal lobe epilepsy	40 yrs. old	2–4 every few weeks in clusters	LMT 2 h before surgery

AED Abbreviations: CBZ, carbamazepine; TPM, topiramate; LEV, levetiracetam; LMT, lamotrigine; GBP, gabapentin; PGB, pregabalin; NA, not available.




Fig. 1. Experimental approach. (A) We selected drug resistant epileptic patients receiving CBZ prior to surgery. The exact time and dosage of drug administration were noted. Brain and blood samples were collected at time of resection. Each brain specimen was processed to give a sample for the establishment of primary brain endothelial cell culture and a comparable sample for *ex vivo* HPLC-UV analysis. (B) Primary brain endothelial cells were cultured using a flow-based *in vitro* system (DIV) allowing for the formation of a physiologic blood–brain barrier. CBZ and ^{14}C -CBZ were added to the DIV-BBBs. (B–C) Levels of CBZ and its metabolites were measured *ex vivo* (brain and blood samples) and *in vitro* (luminal and extra-luminal sides of the DIV-BBB) using a combination of microdialysis, HPLC-UV, MS and AMS analysis.

Drugs and sample preparations

Carbamazepine (CBZ, catalog number 4024), ^{14}C -carbamazepine (^{14}C CBZ, catalog number C-7737) and carbamazepine 10, 11 epoxide (CBZ-EPO, catalog number 4206) were purchased from Sigma-Aldrich (Saint Louis, MO, USA). Quinolinic acid (QA, catalog number P63204) was purchased from Sigma-Aldrich (Saint Louis, MO, USA). Brain tissues were rinsed with PBS (0.01 M), and homogenized (10 ml/g) in methanol/water (60/40, v/v). Homogenates were vortexed and centrifuged at 2500 rpm for 15 min. Blood samples were centrifuged at 2500 rpm for 10 min to isolate serum. Microdialysis was used to collect free fractions of drug present *in vitro* and *ex vivo* samples. A gas-tight microdialysis syringe (5 ml) was filled with perfusion fluid (methanol/water 60/40, v/v) and DMEM (Dulbecco's Modified Eagle Medium for serum). The syringe is connected to the microdialysis probe (4 mm, catalog number MD-2204, Bioanalytical Systems, USA) using a plastic tube and operated with a pump (flow rate = 1 $\mu\text{l}/\text{min}$, Bioanalytical Systems, Inc., IN, USA). Microdialysis probes have a 320 μm outer diameter, 4 mm membrane length, and a low molecular weight cut off membrane (<5000 Da).

HPLC analysis: CBZ, CBZ-EPO and QA measurement

Chromatographic conditions: Chromatographic separations (HPLC, Agilent 1200 series) were performed using a Zorbax Eclipse Plus C18 stainless steel column (4.6 \times 150 mm, 3.5 μm), supplied by Agilent Technologies Inc, USA (Ghosh et al., 2010, 2011a). The mobile phase consisted of acetonitrile:methanol:water (18:19:63, v/v/v). **Standard solutions:** CBZ and CBZ-EPO were dissolved in methanol (1 mg/ml). Standards (0.5, 5, 10, 20, 40 and 60 $\mu\text{g}/\text{ml}$) were prepared by further dilution of stock solution. Quinolinic acid standard 5 mM stock was prepared in 1 N NaOH (following Sigma-Aldrich specification guidelines) and was further diluted to prepare calibration standards. Solutions were stored at -20°C .

Chromatography was performed at room temperature, flow rate of 1 ml/min and detection performed at 210 nm. **Sampling and extraction procedure:** Brain and serum microdialysis eluates (50 μl) were injected in the column CBZ and CBZ-EPO and QA standard

chromatograms were matched with the profiles obtained from brain and serum samples. Fractions were collected for mass spectrometry analysis.

An alternative method was used for better resolution and separation of the QA-containing fraction and subsequent fractions. The mobile phase consisted of methanol:water:acetic acid (64:35.9:0.1, v/v/v, modified method of Husain et al., 1995). A Zorbax Eclipse Plus C18 stainless steel column (4.6 \times 150 mm, 3.5 μm , Agilent Technologies, USA) was used. Samples were dissolved in the mobile phase. The analysis was performed under isocratic conditions at a flow rate of 0.2 ml/min at room temperature. Analytes were detected at 254 nm. Fractions were collected for mass spectrometry analysis. Both methods were validated based on a standard calibration curve and by determining the limit of quantification, precision and accuracy (see Table 2).

Quantification and sensitivity: Quantifications of serum and brain concentrations of CBZ, CBZ-EPO and QA were achieved by relating peak-area ratios of the drug with the known concentrations on the calibration curve. The slope and correlation coefficients (r) were determined using the least-squares linear regression analysis method. Results from the linearity study showed 0.01–6.16% CV of standard curve based on absorbance values and a correlation of 0.998 between peak-area ratio and concentrations. The limit of quantification (LOQ) is the lowest amount of analyte that can be measured with the defined precision and accuracy. The limit of quantification was calculated by $10 \times (\text{SD}/S)$ where SD represents the standard deviation of the determination and S represents the slope of the calibration curve (Zhang et al., 2009). Under the experimental conditions used, the LOQ was approximately 0.04 (CBZ) and 0.05 (CBZ-EPO) and 0.01 $\mu\text{g}/\text{ml}$ (QA). The coefficient of variation was found to be less than 7%.

Precision and accuracy: The intra-day precision was determined from a replicate analysis of pooled human serum/DMEM containing CBZ, CBZ-EPO and QA at five different concentrations covering low, medium and higher ranges of the calibration curve. Precision was expressed as the percent coefficient of variation (% CV), and accuracy as a percentage of the theoretical concentration (observed concentration \times 100/theoretical concentration). The intra-day precision ranged

Table 2
Precision of carbamazepine, carbamazepine-epoxide, quinolinic acid quantification.

Drugs/metabolites	Concentration added (µg/ml)	Intraday			Correlation (r)
		Measured concentration (mean ± SD)	CV (%) ^a	Accuracy (%) ^b	
Carbamazepine	1	1.043 ± 0.060	5.752	104.30	0.999
	5	4.979 ± 0.157	3.153	99.58	
	10	10.201 ± 0.186	1.823	102.01	
	25	25.351 ± 0.312	1.230	101.40	
	50	49.761 ± 0.305	0.612	99.52	
Carbamazepine-epoxide	1	0.994 ± 0.057	5.734	99.40	0.998
	5	4.973 ± 0.183	3.679	99.46	
	10	9.952 ± 0.023	0.231	99.52	
	25	24.828 ± 0.192	0.773	99.31	
	50	49.939 ± 0.182	0.364	99.87	
QA method-1	0.84	0.838 ± 0.033	3.93	99.76	0.998
	1.68	1.689 ± 0.016	0.945	100.53	
	4.20	4.198 ± 0.213	5.073	99.95	
	8.40	8.422 ± 0.089	1.056	100.26	
	16.80	16.762 ± 0.141	0.841	99.77	
QA method-2	0.84	0.849 ± 0.033	3.866	101.07	0.999
	1.68	1.682 ± 0.018	1.070	100.11	
	4.20	4.221 ± 0.123	2.914	100.50	
	8.40	8.413 ± 0.312	3.708	100.15	
	16.80	16.81 ± 0.213	1.267	100.05	

Mean values represent five different samples of each concentration.

^a Accuracy = 100 (observed concentration/theoretical concentration).

^b CV % or relative standard deviation % = 100 (standard deviation/mean).

from 0.61 to 5.75% CV. Accuracy ranged from 99.40 to 104.30% (Table 2).

Mass-spectroscopy analysis

Samples were fractionated according to peak retention times. HPLC fractions were then collected and processed for MS analysis. Fractions were speed vacuumed, dried and reconstituted in 50 µl of 40% acetonitrile, 0.1% formic acid solutions. LTQ FT Ultra mass spectrometer (Thermo Fisher Scientific, CA) equipped with electrospray ionization (ESI) source was used for all ESI MS analysis. Each fraction was introduced into mass spectrometer by infusion. All MS spectra were acquired in the positive ion mode with the needle voltage of 4.5 kV. A full MS survey scan was recorded in the Fourier Transform (FT) analyzer at resolution R = 100,000 for the *m/z* range of 50–300. The capillary temperature was set at 275 °C. Nitrogen was used as nebulizer and dry gas. The MS tandem analysis was used to confirm the parent drug by generating the fragment ions. For example, under CID conditions in the FTICR cell, the major product ion of *m/z* 194 was observed for CBZ precursor ion with *m/z* of 237 (Supplementary Fig. 1A). MS and tandem MS data were further analyzed by LC-MCD Trap 4.2 Quant Analysis Version 1.5 Software (Bruker Daltonik GmbH, Bremen, Germany) and molecular ions identified by Scripps Center for Mass Spectrometry (<http://metlin.scripps.edu/>).

Accelerator mass spectroscopy, AMS (Tompkins et al., 2006)

This technique routinely prepares and analyzes samples containing extremely low concentrations of ¹⁴C generated in clinical trials. Instrument background levels were consistently in the low 10⁻¹⁶ range (¹⁴C/¹²C). Chemical background was approximately equivalent to 0.4% of natural background levels of ¹⁴C. When samples consisting of ¹⁴C levels 100 times above natural background were repeatedly processed, no increase in system background was observed, either during sample processing or during AMS measurement. Samples prepared and measured in duplicate had a correlation coefficient R² = 0.9987. In AMS, carbon is required to make any measurement; therefore, it is not possible to have a blank sample without having carbon present. Unlabeled CBZ (final concentration in the DIV-BBB of 50 µg/ml and ¹⁴C-labeled CBZ (0.2 dpm/µl in DIV-BBB, specific

activity = 22.6 mCi/mM)) was sufficient to provide detectable signal of the new peaks, possibly related to CBZ metabolism. Considering 1 mCi = 2.2 × 10⁹ dpm, 0.2 dpm/µl in this study was equivalent to 100 pmol/µl.

Statistical analysis

We used Origin 7.0 (Origin Lab, Northampton, MA, USA) and Jump 7.0 software. For all parametric variables, differences between populations were analyzed by ANOVA. In all figures, symbols with error bars indicate mean ± SEM; *p < 0.05 was considered statistically significant.

Results

Patients received carbamazepine (CBZ) prior to surgery as part of their antiepileptic drug (AED) regimen. Brain and blood samples were collected during surgery as described in Fig. 1 and Table 1. These samples were used for brain and serum determination of CBZ metabolites by HPLC paired to accelerated (AMS) or conventional mass spectroscopy (MS). Brain endothelial cells from the same patients were used for *in vitro* studies (Fig. 1 and (Ghosh et al., 2010, 2011a; Santaguida et al., 2006)). As expected (Potschka et al., 2001; Rambeck et al., 2006), CBZ had limited brain permeability (Figs. 2A1–A2). We found blood levels of free CBZ in the range of 1.38–1.50 µg/ml as described by others (Rambeck et al., 2006). While we could not detect CBZ in the brain by using *ex-situ* microdialysis, Rambeck et al. detected µg/g concentration of CBZ by using an intra-operative approach. The variability in the CBZ levels detected in the drug resistant epileptic brain may be due to the different techniques used. However, HPLC fractions in the 2 to 10 min interval contained known CBZ metabolic products. These were almost entirely segregated by brain-derived samples (fractions 1 and 4; note the statistically significant difference in A2).

An obvious obstacle in these studies is the lack of “normal” comparison brain tissue. Thus, brain samples derived from drug resistant patients have no true “controls”, the closest being their “drug respondent” counterpart. However, these samples are very hard to access since epileptics responding to drug therapy almost never undergo brain resective surgery. Data from a patient (see Table 1) undergoing




Fig. 2. Brain endothelial cells metabolize CBZ. (A1–A2) HPLC quantification of serum and brain levels of CBZ. CBZ was absent in brain and detected in blood of drug resistant epileptic subjects ($n = 6$). Note the appearance of signals (retention time: 2–10 min) possibly related to CBZ metabolic products. The latter were predominantly segregated in brain ($P < 0.05$, fractions 1 and 4). (B1) Lack of CBZ penetration was detected across the *in vitro* drug resistant epileptic BBB. This is in contrast to what was seen with brain endothelial cells from a non-drug resistant patient (B2), where no barrier to CBZ passage was measured and where levels in the brain were comparable to serum. (C) Accelerated mass spectroscopy (AMS) analysis indicated that the fractions detected in the multiple drug resistant brains, *in vitro* and *ex vivo*, derived from the parent, radiolabelled ¹⁴C-CBZ. The figure shows ¹⁴C peaks measured in the brain side of the *in vitro* BBB between 2 and 10 min. Peak retention times matched in the two modalities. Note the time-dependent increase of radiolabelled CBZ metabolites. The *bottom* traces show a comparison of HPLC profiles obtained from a drug resistant epileptic and a control sample. Note the absence of signal in the adopted control brain. (* indicates $p < 0.05$, data are presented as mean \pm SEM).

resection for a cerebrovascular event showed that reduced CBZ permeability across the blood–brain barrier appears to be an exclusive property of multiple drug resistant brain (Fig. 2B).

We demonstrated that *in vitro* human brain endothelial cells spare their *in vivo* properties of multiple drug resistance if grown under flow conditions (Desai et al., 2002; Ghosh et al., 2010, 2011a). P450 and MDR1 expression and physiological functions are thus preserved in endothelial cell cultured under dynamic conditions (Desai et al., 2002; Dombrowski et al., 2001; Ghosh et al., 2010). We took advantage of this system to evaluate the pattern of CBZ penetration and metabolism in the DRE and non-DRE *in vitro* BBB (Fig. 2B). Results were compared to data obtained *ex vivo* (Fig. 2C). Low amounts of CBZ were detected in the brain side of the DRE BBB model compared to the non-DRE (Figs. 2B1–B2). Thus, brain endothelial cells derived from drug resistant subjects do not appear to form a barrier to CBZ passage. HPLC-AMS analysis confirmed the presence of CBZ brain metabolites (fractions 1–4, Fig. 2C) which were not detected

in non-DRE brain, but were produced by *in vitro* DRE BBB endothelial cells. Signals contained radioactive carbon and were therefore derived from exogenous ¹⁴C-CBZ (Fig. 1C). Signals were more pronounced in brain-side fractions *ex vivo* and *in vitro*. Taken together, these results support the notion that fractions 1–4 were derived from BBB metabolism of ¹⁴C-CBZ.

Fractions were subsequently analyzed using MS to determine the molecular mass of constituents. In fraction 1 we found a specific m/z of 167.96 and 168.0 in positive ion mode matching the molecular weight of quinolinic acid (QA, Fig. 3, see also Table 2). In the same samples, we measured the protonated form of kynurenine (a precursor of QA, $m/z = 209.03$, Fig. 3, see also Table 3). In fraction 4 we found a molecular component with m/z correspondent to 10, 11-dihydro-10, 11-dihydroxy-carbamazepine (DiOH-CBZ, $m/z = 270.98$ m/z , $M + H^+$) (Fig. 3B). The molecular nature of known CBZ metabolites detected in brain samples was further confirmed using HPLC-UV. For example, we positively identified CBZ-epoxide in these




Fig. 3. MS analysis reveals the presence of QA and DiOH-CBZ. (A–A1) Fraction 1 was collected by HPLC and analyzed by MS. We found $m/z = 167.96$ and 168.0 in positive ion mode matching the molecular weight of quinolinic acid (QA, see also Table 2). A protonated form of kynurenine (a precursor of QA, $m/z = 209.03$) was also detected in this fraction (see Table 2). (B) Fraction 4 contained 10, 11-dihydro-10, 11-dihydroxy-carbamazepine (DiOH-CBZ, $m/z = 270.98$ m/z $M+H^+$) and for molecular ion identification see Table 2. Known CBZ metabolites were identified in the remaining fractions (see Supplementary Fig. 1).




samples (CBZ-EPO, see Supplementary Fig. 1 and Fig. 5). To confirm the presence of quinolinic acid (QA), fraction 1 was further analyzed by two *ad hoc* HPLC protocols (Fig. 4). Regardless of the protocol used, we found similar concentrations ($8.09 \mu\text{M}$ and $7.56 \mu\text{M}$) of QA in the drug resistant brain.

To determine the time course of QA appearance in brain samples, we compared its levels to the time interval from oral administration of CBZ. In the same samples, we determined the levels of CBZ and its metabolites. In the *in vitro* model of the BBB, radioactive fractions containing CBZ derivatives were isolated and analyzed with identical methods as *ex vivo*. A kinetic analysis of QA levels in brain showed that QA was formed at a comparable rate at which a surrogate of the parental drug was metabolized (CBZ-Epoxyde; Fig. 5A and Supplementary Fig. 2). CBZ added to culture media *in vitro* was transformed in QA at a rate of 3% per hour, again comparable to what was observed in the brain (Fig. 5A). Finally, it was necessary to determine whether QA measured in the brain of epileptics was derived from endogenous metabolic processes, other therapeutics or derived especially from CBZ metabolism. The CBZ specificity of QA origin was demonstrated in two patients who took lamotrigine, pregabalin or gabapentin but never used CBZ (Fig. 5B). No QA was detected in the brain tissue from these patients, suggesting that CBZ and not the epileptic condition or associated AED may be the potential source of QA.

Discussion

Our results suggest that in human multiple drug resistant epileptic brain QA may be a result of P450-mediated CBZ metabolism. Our findings were obtained in a “translational” framework, since we explored drug metabolism directly in human subjects and in an *in vitro* model using the very same subjects’ cells. These results also provide an insight into the unknowns and complexity of “personalized neuropharmacology”. Whether the brain itself or liver cells are responsible for this surprising finding remains undetermined, but our data suggest at least a partial metabolic role for CNS endothelial cells. The lack of measurable CBZ in the CNS may be due to the concomitant action of BBB metabolic machinery (Ghosh et al., 2010, 2011a, 2011b) along with efflux transporters (Loscher and Potschka, 2005; Marchi et al., 2010a; Rambeck et al., 2006).

Table 3
Molecular ions of each compound.

Compounds	Mass	$[M+H]^+$	Formula	Structure
Quinolinic acid	167.02	168.02	$C_7H_5NO_4$	
Kynurenine	208.08	209.08	$C_{10}H_5N_2O_3$	
10,11-dihydro-dihydroxy carbamazepine	270.10	271.10	$C_{15}H_{14}N_2O_3$	




Fig. 4. HPLC-UV determination of quinolinic acid (QA). (A–B) The presence of QA in fraction 1 was confirmed using two *ad hoc* HPLC-UV methods. (A1–B1) Levels of QA are significantly higher in the brain compared to serum. Brain levels detected using the two methods were identical (8.09 μM and 7.56 μM); note that the elution time of standards matched chromatograms of brain or serum samples (2.9 and 6.8 min in A and B respectively). (A2–B2) Dose response of QA was performed using two HPLC methods (* indicates $p < 0.05$, data are presented as mean \pm SEM).

While conclusive evidence linking QA to CBZ in human brain would require *in vivo* tracer experiments, we believe that the following considerations strongly support the presence of as yet unknown metabolic pathways responsible for CNS CBZ metabolism. The parental (CBZ) origin of QA was supported by the following: 1) ^{14}C -CBZ metabolites were found in QA-containing fractions; 2) QA presence in fraction 1 was confirmed by MS and by two independent HPLC methods; 3) The rate of QA formation by brain EC *in vitro* was comparable to the rate of CBZ metabolism and QA production *ex vivo*, suggesting that a common pathway may be involved; and, 4) QA was not detected in brain of patients who took AEDs other than CBZ or in a control. The latter, in our opinion, suggests that the influence of CBZ on the traditional metabolic machinery for QA production is not necessary for CBZ conversion to QA.

Others have mapped QA to the epileptic brain, and its presence appears to be related to abnormal spiking activity typical of the seizure-prone brain (Fedi et al., 2003). Remarkably, all patients in this study were undergoing CBZ therapy, further supporting the

exogenous origin of at least some of the QA present in the brain. However, CBZ enhances production of kynurenic acid (Kocki et al., 2004), a member of the tryptophan-QA pathway. Kynurenine (Kyn) was identified by us in fraction 1. Since the levels of quinolinic acid (seizure agonist) and kynurenic acid (seizure antagonist) are both elevated in certain pathologies (Stone and Darlington, 2002) the final outcome of their presence is dictated by their ratio. Thus, the true potentiality for an endogenous convulsant derived from CBZ ultimately rests on the availability of kynurenic acid (KA) as well as that of QA.

While the metabolic machinery involved in CBZ metabolism to QA is unknown, others have shown that CBZ is transformed into 9-hydroxymethyl-10-carbamoyl acridan (9-acridan) (Breton et al., 2005). In our experiments, CBZ was ^{14}C -labeled in the carbonyl group which is preserved in 9-acridan and in QA as carboxylic acid (Fig. 6 and Supplementary Fig. 3). Thus, the initial steps of CBZ conversion into QA implicate a step consisting of 9-acridan formation carbamazepine-epoxide, CBZ-EPO followed by 10, 11-dihydro-10, 11-dihydroxy-carbamazepine, DiOH-CBZ (Breton et al., 2005).




Fig. 5. Time course of QA production. (A) Note that the axes in this panel refer to both CBZ-EPO (black ink) and QA (red ink). *Ex vivo* data: time-dependent disappearance of CBZ-epoxide (a known CBZ metabolite, black symbols) and appearance of QA (in red) occur at comparable rates. *In vitro*, brain EC produces QA at a rate of 3% per hour again similar to *ex vivo*; the figure depicts values obtained by MS-AMS analysis of ^{14}C labeled CBZ and its products (see also Fig. 2C). (B) No QA was detected in samples from patients administered with AEDs other than CBZ.




Fig. 6. Proposed scheme of carbamazepine metabolism and quinolinic acid formation in the drug resistant epileptic brain. Carbamazepine metabolism by either liver (Fertig, 2008) or BBB EC (Ghosh et al., 2010, 2011a; Granata et al., 2009) results in the formation of known metabolites carbamazepine 10, 11, epoxide (CBZ-EPO) and 10, 11-dihydro-10, 11-dihydroxy-carbamazepine (DiOH-CBZ). The published rate of CBZ metabolism *ex vivo* and in multiple drug resistant patients is approximately 4% (Fertig, 2008). BBB endothelial cell metabolism *in vitro* led to the formation of quinolinic acid (QA, Fig. 5) and perhaps of its precursor, kynurenine (Kyn). While the exact metabolic steps remain to be elucidated, we propose the following scenarios: 1) Liver enzymes (P450) produce CBZ-EPO and possibly QA, while brain cells may metabolize CBZ to QA; 2) In our experiments we could not estimate CBZ rate of metabolism by direct CNS determinations since no CBZ was found in the CNS (Fig. 2). We therefore used CBZ-EPO as a surrogate marker. The measured rate of CBZ metabolism to CBZ-EPO was similar to the measured appearance of brain QA; (~3% per hour as shown in Fig. 5). The proposed link between known CBZ metabolites and QA also implicates 9-acridan, a product of DiOH-CBZ conversion by leukocytes (Breton et al., 2005). Again, whether this process in epileptics occurs in circulating or resident white blood cells remains unknown, but recent findings have shown limited presence of lymphocytes in the epileptic brain (Marchi et al., 2010b). Note that the radiolabelled carbon atom is shown as a red dot in parental and daughter drugs.

QA is an endogenous convulsive agent metabolized from tryptophan (Erhardt et al., 2009; Natsume et al., 2003) via the kynurenine pathway. Inflammatory conditions stimulate the breakdown of tryptophan (TRP) into L-kynurenine (Kyn), with the involvement of indoleamine 2,3-dioxygenase (IDO) thereby reducing the availability of TRP (Heyes et al., 1996; Raison et al., 2010). Subsequent reactions catalyzed by kynurenine 3-hydroxylase, kynureninase, and 3-hydroxyanthranilate-3,4-dioxygenase convert Kyn into a NMDA receptor agonist, QA, or may yield a NMDA receptor antagonist, KA (Heyes et al., 1996; Schwarcz et al., 1987). QA causes CNS damage by activating NMDA receptors (Stone and Perkins, 1981), partly by producing mitochondrial dysfunction (Bordelon et al., 1997) and partly by increasing free-radical generation (Behan et al., 1999). Additionally, a role for P450-mediated metabolic induction of KA and QA has been reported (DiNatale et al., 2010; Wu et al., 2011). P450 enzymes are found to be specifically upregulated in the BBB of multiple drug resistant epileptics (Ghosh et al., 2010). CBZ is transformed into 9-acridan by leukocytes (Breton et al., 2005). Leukocytes and macrophages also release QA (Heyes et al., 1996; Smith et al., 2001), and increasing evidence links activated leukocytes to epilepsy (Fabene et al., 2008; Marchi et al., 2009). Thus, while our results support an endothelial origin for QA in patients receiving CBZ, a contribution by leukocytes cannot be ruled out. In addition, whether or not CBZ metabolic conversion to QA implicates tryptophan or L-kynurenine is presently unknown (Fig. 6).

The concentrations measured in the human epileptic brain (~10 μM) were in the range of neurotoxic and seizure promoting levels (During et al., 1989). Since QA levels in the brain are topographically overlapping with abnormal epileptiform activity, we propose a scenario where multiple drug resistance not only impedes CBZ access to the brain, but also leads to exacerbation of seizures by a powerful metabolic process. Our findings may thus reconcile two opposing views of pharmacoresistance, the “kinetic” and “dynamic” hypotheses, both mediated by the “drug resistant BBB phenotype”.

Funding

This work is supported by National Institute of Health – R01NS43284, R41MH093302 and R21HD057256 awarded to Dr. Damir Janigro and by Epilepsy Foundation Research Grant awarded to Dr. Nicola Marchi.

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.nbd.2012.03.010.

Acknowledgments

We thank Accium BioSciences Inc. (Seattle, WA, USA) for generating AMS data. We are also indebted to Dr. Robert Schwarz (Professor of Psychiatry, University of Maryland, Baltimore, USA) who critically reviewed part of this work.

References

- Behan, W.M.H., McDonald, M., Darlington, L.G., Stone, T.W., 1999. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. *Br. J. Pharmacol.* 128, 1754–1760.
- Bordelon, Y.M., Chesselet, M.F., Nelson, D., Welsh, F., Erecinska, M., 1997. Energetic dysfunction in quinolinic acid-lesioned rat striatum. *J. Neurochem.* 69, 1629–1639.
- Breton, H., Cociglio, M., Bressolle, F., Peyriere, H., Blayac, J.P., Hillaire-Buys, D., 2005. Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. *J. Chromatogr. B* 828, 80–90.
- Cucullo, L., Hossain, M., Rapp, E., Manders, T., Marchi, N., Janigro, D., 2007. Development of a humanized *in vitro* blood–brain barrier model to screen for brain penetration of antiepileptic drugs. *Epilepsia* 48, 505–516.
- Cucullo, L., Couraud, P.O., Weksler, B., Romero, I.A., Hossain, M., Rapp, E., Janigro, D., 2008. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. *J. Cereb. Blood Flow Metab.* 28, 312–328.
- Desai, S.Y., Marroni, M., Cucullo, L., Krizanac-Bengez, L., Mayberg, M.R., Hossain, M.T., Grant, G.G., Janigro, D., 2002. Mechanisms of endothelial survival under shear stress. *Endothelium* (New York) 9, 89–102.
- DiNatale, B.C., Murray, I.A., Schroeder, J.C., Flaveny, C.A., Lahoti, T.S., Laurenzana, E.M., Omiecinski, C.J., Perdey, G.H., 2010. Kynurenine acid is a potent endogenous aryl

- hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. *Toxicol. Sci.* 115, 89–97.
- Dombrowski, S.M., Desai, S.Y., Marroni, M., Cucullo, L., Goodrich, K., Bingaman, W., Mayberg, M.R., Bengez, L., Janigro, D., 2001. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. *Epilepsia* 42, 1501–1506.
- During, M.J., Freese, A., Heyes, M.P., Swartz, K.J., Markey, S.P., Roth, R.H., Martin, J.B., 1989. Neuroactive metabolites of L-tryptophan, serotonin and quinolinic acid, in striatal extracellular fluid – effect of tryptophan loading. *FEBS Lett.* 247, 438–444.
- Erhardt, S., Olsson, S.K., Engberg, G., 2009. Pharmacological manipulation of kynurenic acid potential in the treatment of psychiatric disorders. *CNS Drugs* 23, 91–101.
- Fabene, P.F., Mora, G.N., Martinello, M., Rossi, B., Merigo, F., Ottoboni, L., Bach, S., Angiari, S., Benati, D., Chakir, A., Zanetti, L., Schio, F., Osculati, A., Marzola, P., Nicolato, E., Homeister, J.W., Xia, L.J., Lowe, J.B., Mcever, R.P., Osculati, F., Sbarbati, A., Butcher, E.C., Constantin, G., 2008. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. *Nat. Med.* 14, 1377–1383.
- Fedi, M., Reutens, D.C., Andermann, F., Okazawa, H., Boling, W., White, C., Dubeau, F., Nakai, A., Gross, D.W., Andermann, E., Diksic, M., 2003. Alpha-[C-11]-methyl-L-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. *Epilepsy Res.* 52, 203–213.
- Fertig, E.J.M.R.H., 2008. Carbamazepine. In: Engel, J., Pedley, T.A. (Eds.), *Epilepsy: A Comprehensive Textbook*. Wolters-Kluwer, Philadelphia, PA, pp. 1543–1555.
- Ghosh, C., Gonzalez-Martinez, J., Hossain, M., Cucullo, L., Fazio, V., Janigro, D., Marchi, N., 2010. Pattern of P450 expression at the human blood–brain barrier: roles of epileptic condition and laminar flow. *Epilepsia* 51, 1408–1417.
- Ghosh, C., Marchi, N., Desai, N.K., Puvenna, V., Hossain, M., Gonzalez-Martinez, J., Alexopoulos, A.V., Janigro, D., 2011a. Cellular localization and functional significance of CYP3A4 in the human epileptic brain. *Epilepsia* 52, 562–571.
- Ghosh, C., Puvenna, V., Gonzalez-Martinez, J., Janigro, D., Marchi, N., 2011b. Blood–brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. *Curr. Drug Metab.* 12, 742–749.
- Granata, T., Marchi, N., Carlton, E., Ghosh, C., Gonzalez-Martinez, J., Alexopoulos, A.V., Janigro, D., 2009. Management of the patient with medically refractory epilepsy. *Expert Rev. Neurother.* 9, 1791–1802.
- Grant, G.A., Abbott, N.J., Janigro, D., 1998. Understanding the physiology of the blood–brain barrier: *in vitro* models. *News Physiol. Sci.* 13, 287–293.
- Heyes, M.P., Achim, C.L., Wiley, C.A., Major, E.O., Saito, K., Markey, S.P., 1996. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. *Biochem. J.* 320, 595–597.
- Husain, S., Khalid, S., Nagaraju, V., Rao, R.N., 1995. High-performance liquid-chromatographic separation and determination of small amounts of process impurities of ciprofloxacin in bulk drugs and formulations. *J. Chromatogr. A* 705, 380–384.
- Ju, C., Utrecht, J.P., 1999. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. *J. Pharmacol. Exp. Ther.* 288, 51–56.
- Kocki, T., Kocki, J., Wielosz, M., Turski, W.A., Urbanska, E.M., 2004. Carbamazepine enhances brain production of kynurenic acid *in vitro*. *Eur. J. Pharmacol.* 498, 325–326.
- Kwan, P., Schachter, S.C., Brodie, M.J., 2011. Current concepts drug-resistant epilepsy. *N. Engl. J. Med.* 365, 919–926.
- Loscher, W., Potschka, H., 2005. Drug resistance in brain diseases and the role of drug efflux transporters. *Nat. Rev. Neurosci.* 6, 591–602.
- Marchi, N., Fan, Q.Y., Ghosh, C., Fazio, V., Bertolini, F., Betto, G., Batra, A., Carlton, E., Najm, I., Granata, T., Janigro, D., 2009. Antagonism of peripheral inflammation reduces the severity of status epilepticus. *Neurobiol. Dis.* 33, 171–181.
- Marchi, N., Gonzalez-Martinez, J., Nguyen, M.T., Granata, T., Janigro, D., 2010a. Transporters in drug-refractory epilepsy: clinical significance. *Clin. Pharmacol. Ther.* 87, 13–15.
- Marchi, N., Teng, Q.S., Ghosh, C., Fan, Q.Y., Nguyen, M.T., Desai, N.K., Bawa, H., Rasmussen, P., Masaryk, T.K., Janigro, D., 2010b. Blood–brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. *Brain Res.* 1353, 176–186.
- Natsume, J., Kumakura, Y., Bernasconi, N., Soucy, J.P., Nakai, A., Rosa, P., Fedi, M., Dubeau, F., Andermann, F., Lisbona, R., Bernasconi, A., Diksic, M., 2003. Alpha-[C-11] methyl-L-tryptophan and glucose metabolism in patients with temporal lobe epilepsy. *Neurology* 60, 756–761.
- Potschka, H., Fedrowitz, M., Loscher, W., 2001. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. *Neuroreport* 12, 3557–3560.
- Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Spivey, J.R., Saito, K., Miller, A.H., 2010. CSF concentrations of brain tryptophan and kynurenes during immune stimulation with IFN- α : relationship to CNS immune responses and depression. *Mol. Psychiatry* 15, 393–403.
- Rambeck, B., Jurgens, U.H., May, T.W., Pannek, H.W., Behne, F., Ebner, A., Gorji, A., Straub, H., Speckmann, E.J., Pohlmann-Eden, B., Loscher, W., 2006. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. *Epilepsia* 47, 681–694.
- Santaguida, S., Janigro, D., Hossain, M., Oby, E., Rapp, E., Cucullo, L., 2006. Side by side comparison between dynamic versus static models of blood–brain barrier *in vitro*: a permeability study. *Brain Res.* 1109, 1–13.
- Schwarcz, R., Speciale, C., French, E.D., 1987. Hippocampal kynurenes as etiological factors in seizure disorders. *Pol. J. Pharmacol. Pharm.* 39, 485–494.
- Smith, D.G., Guillemin, G.J., Pemberton, L., Kerr, S., Nath, A., Smythe, G.A., Brew, B.J., 2001. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. *J. Neurovirol.* 7, 56–60.
- Stone, T.W., Darlington, L.G., 2002. Endogenous kynurenes as targets for drug discovery and development. *Nat. Rev. Drug Discov.* 1, 609–620.
- Stone, T.W., Perkins, M.N., 1981. Quinolinic acid – a potent endogenous excitant at amino-acid receptors in CNS. *Eur. J. Pharmacol.* 72, 411–412.
- Tompkins, E.M., Farmer, P.B., Lamb, J.H., Jukes, R., Dingley, K., Ubick, E., Turteltaub, K.W., Martin, E.A., Brown, K., 2006. A novel C-14-postlabeling assay using accelerator mass spectrometry for the detection of O-6-methyldeoxy-guanosine adducts. *Rapid Commun. Mass Spectrom.* 20, 883–891.
- Wu, Q., Zhang, Y.-H., Zhao, X., Shi, W.-L., Pu, X.-P., 2011. Proteome studies on liver tissue in a phenobarbital-induced rat model. *Eur. J. Pharmacol.* 670, 333–340.
- Zhang, X.Q., He, Y., Ding, M., 2009. Simultaneous determination of tryptophan and kynurenic acid in plasma samples of children patients with Kawasaki disease by high-performance liquid chromatography with programmed wavelength ultraviolet detection. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 877, 1678–1682.